10-K: Kintara Therapeutics Terminates VAL-083 Program, Focuses on REM-001, and Approves Merger with TuHURA Biosciences

Kintara Therapeutics shifts its focus to REM-001 after VAL-083 fails to outperform standard care in glioblastoma, and stockholders approve a merger with TuHURA Biosciences.

Summary

• Kintara Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer therapies.
• The company's lead candidate is REM-001, a photodynamic therapy for cutaneous metastatic breast cancer (CMBC).
• Kintara terminated the development of VAL-083 after it failed to show better results than current standards of care in a glioblastoma study.
• The company received a $2 million NIH grant to support the clinical development of REM-001.
• A 15-patient open-label study of REM-001 in CMBC is underway, with four patients dosed as of October 7, 2024.
• Kintara's stockholders approved a reverse stock split and a merger with TuHURA Biosciences, expected to close in mid-October 2024.
• Post-merger, Kintara stockholders are expected to own approximately 2.85% of the combined company, or 5.45% including contingent value rights (CVR).
• The company expects to complete enrollment in the REM-001 study in the fourth calendar quarter of 2024.
• Historical data suggests REM-001 achieved complete responses in approximately 80% of evaluable tumor sites in previous studies.
• Kintara reported a net loss of approximately $8.5 million for the fiscal year ended June 30, 2024, and had cash and cash equivalents of approximately $4.9 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as the NIH grant and the focus on REM-001, the termination of VAL-083, the company's financial instability, and the need for additional funding raise significant concerns. The merger with TuHURA is a potential positive, but its success is not guaranteed.

Positives

• The company is focusing on REM-001, a promising therapy for CMBC with a high historical response rate.
• The $2 million NIH grant provides significant funding for the REM-001 clinical program.
• The merger with TuHURA Biosciences could provide strategic benefits and additional resources.
• The company has received a Study May Proceed letter from the FDA for the REM-001 study.
• The FDA has granted Fast Track Designation for REM-001 in CMBC.

Negatives

• The termination of the VAL-083 program represents a setback for the company's pipeline.
• The company has a history of operating losses and an accumulated deficit of approximately $159.9 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is not currently in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
• The company is dependent on third-party suppliers and manufacturing organizations for both commercial and clinical study supplies.

Risks

• The company may not be able to raise sufficient additional capital to fund its operations.
• The company's common stock may be delisted from The Nasdaq Capital Market if it does not regain compliance with the minimum bid price requirement.
• The company may not be able to successfully commercialize REM-001 or any other product candidates.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The company is dependent on third parties for clinical studies and manufacturing.
• The company may be subject to product liability claims.
• The company may not realize the anticipated benefits of the merger with TuHURA.
• The company may be subject to foreign exchange fluctuation.

Future Outlook

The company expects to complete enrollment of patients in the REM-001 Study in the fourth calendar quarter of 2024 and the merger with TuHURA is expected to be consummated in mid-October 2024, subject to regulatory approval and the satisfaction of the remaining closing conditions under the Merger Agreement.

Management Comments

• Management is pursuing various financing alternatives to fund operations.
• Management plans to secure financing through new equity issues and strategic partnerships if the merger is not consummated.

Industry Context

The oncology market is highly competitive, with numerous large pharmaceutical and biotechnology companies developing cancer therapies. Kintara is focusing on rare, unmet medical needs, particularly in areas where tumors can be accessed with a light delivery fiber device, which may provide a niche market opportunity.

Comparison to Industry Standards

• The termination of the VAL-083 program is not uncommon in the pharmaceutical industry, where clinical trials often fail to meet endpoints.
• The company's focus on orphan cancer indications is a common strategy for smaller biotech companies to gain regulatory advantages and market exclusivity.
• The company's reliance on third-party manufacturers and CROs is typical for clinical-stage companies.
• The company's financial situation, with significant losses and a need for additional funding, is common among clinical-stage biotech companies.

Related Party Transactions

• The company has a royalty agreement with Valent Technologies, LLC, a related party, for the commercialization of VAL-083.
• The company has a milestone payment and royalty agreement with St. Cloud Investments, LLC, related to the acquisition of REM-001.

Stakeholder Impact

• Shareholders will experience dilution from the merger with TuHURA and potential future equity offerings.
• Employees may face uncertainty due to the merger and potential restructuring.
• Patients may benefit from the development of REM-001, a potential new treatment for CMBC.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• Complete enrollment of patients in the REM-001 Study in the fourth calendar quarter of 2024.
• Complete the merger with TuHURA Biosciences, expected in mid-October 2024.
• Continue to seek additional funding through various financing alternatives.
• Advance the clinical development of REM-001.

Key Dates

Keywords

REM-001, photodynamic therapy, cutaneous metastatic breast cancer, CMBC, VAL-083, glioblastoma, merger, TuHURA Biosciences, clinical trial, NIH grant, reverse stock split, FDA, orphan drug designation